The U.S. Food and Drug Administration issued new guidance for vaccine makers as the regulatory agency is preparing for the possibility of needing to approve Covid-19 booster shots against variants of the SARS-CoV-2 virus.

GlaxoSmithKline and Sanofi started a new clinical trial of their protein-based Covid-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot’s launch.

A Covid-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio “will not be ready this year,” the French drugmaker’s chief executive told Le Journal du Dimanche newspaper.

CureVac N.V. – a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid – announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, an mRNA-based COVID-19 vaccine candidate in late-stage clinical testing.

After months of touting its efficacy to the western world, the efficacy of Russia’s Sputnik V vaccine was validated in a peer-reviewed study published in The Lancet.

The data continues to come in on the various Covid-19 variants, and so far the news is pretty good, according to BioSpace.

Sanofi will fill and pack millions of doses of Pfizer’s Covid-19 vaccine from July in an effort to help meet the huge demand for the U.S. drugmaker’s shots.

Moderna started development on a booster to the company’s Covid-19 vaccine, which is hoped to work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.

Moderna believes the company’s Covid-19 vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South Africa variant after concluding that the antibody response could be diminished.

Researchers are working on a type of vaccine technology using nanoparticles that is less expensive and does not need to be stored at very low temperatures compared to the mRNA technology used by BioNTech-Pfizer and Moderna to develop vaccines against Covid-19.